ARA-290 (Cibinetide)

ARA-290, a non-erythropoietic peptide, represents a significant advancement in neuroprotective therapies, particularly for small fiber neuropathy. Engineered to activate the innate repair receptor (IRR) pathway, it offers tissue protection without stimulating red blood cells. Phase II clinical trials have shown efficacy in improving metabolic control and neuropathic symptoms among diabetic patients and individuals with sarcoidosis. With a promising safety profile and ongoing research into various therapeutic applications, ARA-290 is poised to make a considerable impact in neuropathy treatment.

Intelligence Profile

Safety Profile

Safety Profile of ARA-290 (Cibinetide)

Limited Safety Data Available

The safety profile of ARA-290 (cibinetide) is not well-established based on currently available evidence. While several clinical trials have been conducted, detailed safety and adverse event data from these studies are not provided in the available literature.

Clinical Trial Status and Safety Implications

The available clinical trial information reveals some concerning patterns:

At least one Phase 2 trial for diabetic macular edema was terminated (NCT06626971), though the reasons for termination are not specified
Another trial investigating effects in type 2 diabetes has unknown status (NCT01933529)
Completed trials include studies in sarcoidosis-related neuropathy and cognitive effects, but safety outcomes from these studies are not detailed in the available evidence

Preclinical Safety Observations

Animal studies suggest ARA-290 may have biological activity across multiple organ systems:

Cardiovascular effects: Studies show cardiac inflammation reduction and effects on heart function
Neurological activity: Demonstrated effects on brain tissue and peripheral nerves
Bone metabolism: Evidence of effects on bone mineral density and osteoclast activity
Kidney function: Tested in models of nephrotoxicity

However, these studies do not provide comprehensive toxicology or safety data.

Evidence Limitations

The evidence base has significant gaps regarding:

Specific adverse events and their frequency
Drug interactions
Contraindications
Populations that should avoid the compound
Long-term safety data
Maximum tolerated doses

Recommendations

Given the limited safety data available, healthcare providers should exercise extreme caution with ARA-290. Any use should be within the context of properly designed clinical trials with appropriate safety monitoring.

Medical Disclaimer: This information is for educational purposes only and should not be used for medical decision-making. Consult qualified healthcare professionals for medical advice regarding any potential therapeutic use of this compound.